Media / News
Green Vision and Anesiva Announce Exclusive Marketing & Distribution Agreement
for Zingo (TM) in Eight Countries in the Middle East
UAE, Saudi, Kuwait, Qatar, Bahrain, Oman, Lebanon & Jordan
“Zingo™ – A FAST ACTING LOCAL ANESTHETIC APPROVED BY THE FDA”
Zingo™ has been shown to provide local analgesia in 1 to 3 minutes prior to peripheral IV starts
and blood draws in children three to 18 years of age.
Doha (Qatar) – April 29, 2008 – Green Vision announced today an agreement with Anesiva, Inc. a
US company based in San Francisco granting it an exclusive license for the marketing and
distribution of Anesiva's Zingo™ (lidocaine hydrochloride monohydrate) powder intradermal
injection system in eight countries in the Middle East region: UAE, Saudi, Kuwait, Qatar, Bahrain,
Oman, Lebanon & Jordan. Under the terms of the agreement, Green Vision will oversee all
necessary regulatory filings, and will be responsible for all marketing and sales of Zingo™ in the
Middle East.
IV insertions and venipunctures are known to cause significant pain and fear in children, therefore
the American Academy of Pediatrics and the American Pain Society encourage physicians to
consider the use of local anesthetics to soothe and minimize the distress resulted from
procedures like venipunctures. It is estimated that there are annually over 2 million cases in
children experiencing pain and fear as a result of peripheral venous punctures and blood draws in
the Middle East countries covered by this agreement.
About Zingo™
Zingo™ is an easy-to-administer, single-use, needle-free system that delivers sterile lidocaine
powder to provide topical, local anesthesia to reduce the pain associated with peripheral I.V.
insertions or blood draws. Zingo’s rapid onset of action allows intravenous line placement or
venipuncture to begin one to three minutes after administration. Zingo is approved to reduce the
pain associated with peripheral IV insertions or blood draws in children three to 18 years of age. In
clinical trials, the most common adverse events with Zingo were redness (erythema), red dots
(petechiae) and swelling (edema).
About Anesiva and its Pipeline of Pain Products
Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the
development and commercialization of novel pharmaceutical products for pain management. The
company has one FDA-approved product, Zingo™, for the reduction of pain associated with
peripheral venous access procedures in children ages three to 18. The second product in
Anesiva's pipeline, Adlea™, has been shown to reduce pain after only a single administration for
weeks to months in multiple settings mid-stage clinical trials for site-specific, acute and chronic,
moderate-to-severe pain. Anesiva is based in South San Francisco, CA, USA. For more information
about Anesiva's leadership in the development of products for pain management, and an overview
of the clinical challenges being addressed by its product candidates, go to www.anesiva.com
Green Vision is committed to provide patients in the Middle East region with safe, effective and
affordable products that will improve quality of life. To achieve this mission Green Vision
acquires and in-licenses products from well-advanced worldwide companies for the Middle
East Market. For further information you can email Green Vision: marketing@greensvision.com
Green Vision and Anesiva Announce Exclusive Marketing & Distribution Agreement
for Zingo (TM) in Eight Countries in the Middle East
UAE, Saudi, Kuwait, Qatar, Bahrain, Oman, Lebanon & Jordan
“Zingo™ – A FAST ACTING LOCAL ANESTHETIC APPROVED BY THE FDA”
Zingo™ has been shown to provide local analgesia in 1 to 3 minutes prior to peripheral IV starts
and blood draws in children three to 18 years of age.
Doha (Qatar) – April 29, 2008 – Green Vision announced today an agreement with Anesiva, Inc. a
US company based in San Francisco granting it an exclusive license for the marketing and
distribution of Anesiva's Zingo™ (lidocaine hydrochloride monohydrate) powder intradermal
injection system in eight countries in the Middle East region: UAE, Saudi, Kuwait, Qatar, Bahrain,
Oman, Lebanon & Jordan. Under the terms of the agreement, Green Vision will oversee all
necessary regulatory filings, and will be responsible for all marketing and sales of Zingo™ in the
Middle East.
IV insertions and venipunctures are known to cause significant pain and fear in children, therefore
the American Academy of Pediatrics and the American Pain Society encourage physicians to
consider the use of local anesthetics to soothe and minimize the distress resulted from
procedures like venipunctures. It is estimated that there are annually over 2 million cases in
children experiencing pain and fear as a result of peripheral venous punctures and blood draws in
the Middle East countries covered by this agreement.
About Zingo™
Zingo™ is an easy-to-administer, single-use, needle-free system that delivers sterile lidocaine
powder to provide topical, local anesthesia to reduce the pain associated with peripheral I.V.
insertions or blood draws. Zingo’s rapid onset of action allows intravenous line placement or
venipuncture to begin one to three minutes after administration. Zingo is approved to reduce the
pain associated with peripheral IV insertions or blood draws in children three to 18 years of age. In
clinical trials, the most common adverse events with Zingo were redness (erythema), red dots
(petechiae) and swelling (edema).
About Anesiva and its Pipeline of Pain Products
Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the
development and commercialization of novel pharmaceutical products for pain management. The
company has one FDA-approved product, Zingo™, for the reduction of pain associated with
peripheral venous access procedures in children ages three to 18. The second product in
Anesiva's pipeline, Adlea™, has been shown to reduce pain after only a single administration for
weeks to months in multiple settings mid-stage clinical trials for site-specific, acute and chronic,
moderate-to-severe pain. Anesiva is based in South San Francisco, CA, USA. For more information
about Anesiva's leadership in the development of products for pain management, and an overview
of the clinical challenges being addressed by its product candidates, go to www.anesiva.com
Green Vision is committed to provide patients in the Middle East region with safe, effective and
affordable products that will improve quality of life. To achieve this mission Green Vision
acquires and in-licenses products from well-advanced worldwide companies for the Middle
East Market. For further information you can email Green Vision: marketing@greensvision.com
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| Green Vision Company Middle East Region Doha, Qatar ph +974-4517815 fax +974--4517247 marketing@greensvision.com |